Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Zhejiang University | OTHER |
| The First Affiliated Hospital of the Fourth Military Medical University | OTHER |
Not provided
Not provided
Not provided
Not provided
According to the latest WHO Classification of Neuroendocrine Neoplasms (NET) in 2019, pancreatic neuroendocrine neoplasms (PNET) are divided into well-differentiated and poorly differentiated PNETs.The former is divided into G1, G2, and well differentiated G3.There are few studies on the survival outcomes of these two differentiated PNET types.The G3 imaging manifestations of the two types of differentiation have not been studied yet, and G3 PNET is often clinically misdiagnosed as pancreatic cancer, so it is necessary to differentiate the imaging manifestations and survival time of the two types.
A total of 71 patients with PNET in our hospital from January 2012 to January 2019 and 58 patients with pancreatic cancer from February 2014 to August 2015 were retrospectively collected. Complete survival time data of all patients after telephone follow-up were obtained.Since G3 PNET is very rare, the investigators enrolled 9 patients with G3 PNET in the First Affiliated Hospital of Zhejiang University School of Medicine and 7 patients with G3 PNET in the Affiliated Hospital of Air Force Military Medical University from January 2013 to October 2018.
CT images of PNET and pancreatic cancer were analyzed independently by two radiologists specializing in abdominal diagnosis, in which G3 lesions were evaluated simultaneously on MRI images and the others were evaluated only on CT images.Records clinical data and imaging characteristics: gender, age, tumor markers, tumor shape, size, tumor characteristics, edge, the expansion of the shrinking, pancreas, pancreatic pancreatitis, enhancement scan, arterial phase and portal phase lesions and the ratio of pancreatic parenchyma around, liver metastasis, peripheral vascular invasion, lymph node metastasis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group PNETs | The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018 |
| |
| Group PDAC | Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | Retrospective study without intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Tumor size | Maximum surface size of the lesion (cm) | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Tumor location | Locations of the pancreas: head, neck, body and tail | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Number of lesions | Number of lesions | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Margin | well-defined or ill-defined | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| tumor texture | solidï¼›solid and cysticï¼›complex cystic | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Pancreatic tail contraction | yes or no | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Complicated pancreatitis | yes or no | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Pancreatic duct/bile duct dilatation |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018, and consecutive patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Risheng Yu | Second Affiliated Hospital of Zhejiang University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang | 310009 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
yes or no
| preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Extrapancreatic tissue invasion | yes or no | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Hepatic metastasis | yes or no | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| Lymphatic metastasis | yes or no | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of pancreas plain scan | CT value of pancreas plain scan | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of lesion plain scan | CT value of lesion plain scan | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of pancreas artery phase | CT value of pancreas artery phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of lesion artery phase | CT value of lesion artery phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of pancreas portal phase | CT value of pancreas portal phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| CT value of lesion portal phase | CT value of lesion portal phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy |
| ID | Term |
|---|---|
| D007516 | Adenoma, Islet Cell |
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D000236 | Adenoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004701 | Endocrine Gland Neoplasms |
| D004066 | Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided